Abstract:Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor modelCabozantinib is a tyrosine kinase inhibitor approved for use in all patients with metastatic renal cell carcinoma (mRCC). Its main target is VEGFR-2 conferring its strong anti-angiogenetic properties. Beside its role in aberrant angiogenesis during tumor growth, VEGF has also been described to be implicated in the accumulation of myeloid-derived suppressor cells (MDSC) in the tumor [1].… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.